Sarepta Therapeutics (SRPT -7.6%) reversed an early gain to continue its descent lower today, despite issuing a positive update from Phase IIb testing of its eteplirsen drug treatment for Duchenne muscular dystrophy. The company says data continues to show a statistically significant clinical benefit for patients after 62 weeks. Unfortunately, the stock has been in a steady decline since the company gave its presentation at the Deutsche Bank 2012 dbAccess BioFEST Conference in Boston on Tuesday.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs